Journal article
Neonatal Subcutaneous BCG Vaccination Decreases Atherosclerotic Plaque Number and Plaque Macrophage Content in ApoE−/− Mice
S Bekkering, K Singh, H Lu, AP Limawan, CA Nold-Petry, MJ Wallace, N Curtis, S Pepe, M Cheung, DP Burgner, T Moss
Biology | MDPI | Published : 2022
Abstract
Bacille-Calmette Guérin (BCG) modulates atherosclerosis development in experimental animals, but it remains unclear whether neonatal BCG vaccination is pro- or anti-atherogenic. Many animal models differ fundamentally from BCG administration to human infants in terms of age, vaccine preparation, dosing schedule, and route of administration. We aimed to elucidate the effect of neonatal subcutaneous BCG vaccination—analogous to human BCG vaccination—on atherosclerosis development in ApoE−/− mice. At 2 days of age, a total of 40 ApoE−/− mice received either a weight-equivalent human dose of BCG, or saline, subcutaneously. From 4 weeks onwards, the mice were fed a Western-type diet containing 22..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This research was funded by the National Health and Medical Research Council of Australia (Program grant 606789, Centre for Research Excellence 1057514, Research Fellowships 1043294 to T.M. and 1064629 to D.P.B.), Investigator Grant to D.P.B. (1175744); Heart Foundation Australia (Grant-inAid G12M6422); and the Victorian Government's Operational Infrastructure Support Program. S.B. is supported by a Rubicon grant from the Dutch Research Council (NWO, No.452173113). D.P.B. is an Honorary Future Fellow of the National Heart Foundation (Australia, No.100026). Investigator Grant Leadership 1 [Grant 1173584] to C.A.N.P., a Future Leader Fellowship from the National Heart Foundation of Australia [CF14/3517] to C.A.N.P. N.C. is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (GNT1197117).I.